SAREPTA THERAPEUTICS, INC. Acquisition Costs, Period Cost
SAREPTA THERAPEUTICS, INC. (SRPT) reported Acquisition Costs, Period Cost of $2.39 million for the 392-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AcquisitionCosts · last filed 2013-05-09
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2012-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2012-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2012-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2012-03-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for fiscal 2012 was $0.00.
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for fiscal 2011 was $0.00.
- SAREPTA THERAPEUTICS, INC. acquisition costs, period cost for fiscal 2010 was $0.00.
| Period end | Acquisition Costs, Period Cost 3 month | Acquisition Costs, Period Cost 6 month | Acquisition Costs, Period Cost 9 month | Acquisition Costs, Period Cost 12 month | Acquisition Costs, Period Cost 371 month | Acquisition Costs, Period Cost 374 month | Acquisition Costs, Period Cost 377 month | Acquisition Costs, Period Cost 380 month | Acquisition Costs, Period Cost 383 month | Acquisition Costs, Period Cost 386 month | Acquisition Costs, Period Cost 389 month | Acquisition Costs, Period Cost 392 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-03-31 | $2.39M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | $2.39M 10-K · filed 2013-03-15 | |||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | -$2.39M 10-Q · filed 2012-11-07 | |||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | -$2.39M 10-Q · filed 2012-08-07 | |||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | -$2.39M 10-Q · filed 2012-05-10 | |||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | -$2.39M 10-K · filed 2012-03-13 | |||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | -$2.39M 10-Q · filed 2011-11-08 | ||||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | -$2.39M 10-Q · filed 2011-08-08 | |||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-10 | |||||||||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-15 | |||||||||||
| 2010-06-30 | -$3.00K 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |